INTRODUCTION Intravenous tissue plasminogen activator (IV tPA) is a globally recommended treatment for acute ischemic stroke patients. We examined IV tPA use among patients aged 18-64 years with a primary diagnosis acute ischemic stroke in the US and inpatient costs per hospitalization by IV tPA use status among these patients. METHODS Using 2010-2013 MarketScan Commercial Claims and Encounte...

Diethyldithiocarbamate (DDTC) injected i.p. inhibits remarkably and in a dose-dependent manner 12-O-tetradecanoylphorbol-13-acetate (TPA)-decreased glutathione (GSH) peroxidase and TPA-induced ornithine decarboxylase (ODC) activities in mouse epidermis in vivo. DDTC is more potent in inhibiting these effects of TPA than 16 other antioxidants, free radical scavengers, thiol-containing compounds,...

Mice lacking the serine protease tissue plasminogen activator (tPA) are resistant to excitotoxin-mediated hippocampal neuronal degeneration. We have used genetic and cellular analyses to study the role of tPA in neuronal cell death. Mice deficient for the zymogen plasminogen, a known substrate for tPA, are also resistant to excitotoxins, implicating an extracellular proteolytic cascade in degen...

Tissue-type plasminogen activator (tPA) regulates physiological processes in the brain, such as learning and memory, and plays a critical role in neuronal survival and neuroinflammation in pathological conditions. Here we demonstrate, by combining mouse in vitro and in vivo data, that tPA is an important element of the cross talk between neurons and astrocytes. The data show that tPA released b...

A potent tumor promoter of mouse skin, 12-O-tetradecanoylphorbol-13-acetate (TPA), inhibits terminal differentiation of Friend erythroleukemia cells (FELC). The differentiation of FELC induced by hexamethylene bisacetamide (HMBA) was almost completely inhibited by the presence of 100 ng TPA per ml (1.7 x 10'' M) for a period of 8 months through 58 serial passages of the cells in a medium contai...

The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) is a potent inducer of differentiation in human promyelocytic leukemia cells. Recently, TPA has been successfully administered to patients with myelocytic leukemia and has produced therapeutic effects that led to temporary remission. These studies demonstrated the potential efficacy of TPA in cancer chemotherapy. We now seek to under...

Signaling theory provides the framework to address three main research questions: (1) How accurately do consumers notice and recollect TPA seals on retail Web sites? (2) How familiar are consumers with major TPA seals? and (3) How accurately do consumers understand the assurances represented by the TPA seals? Results of this study of three major TPA seals (TRUSTe, BBBOnLine Reliability, and Ver...

Papillomas induced in SENCAR mice by initiation with 7,12-dimethylbenz(a)anthracene and promotion by treatment for 10-12 weeks with 12-O-tetradecanoylphorbol-13-acetate (TPA) convert to malignancy at a low frequency. The rate of malignant conversion can be increased by either (a) promoting with TPA for a shorter duration or (h) treatment of papilloma-bearing mice with certain genotoxic chemical...